[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] N-(4-aminobutyl)-N-(3-aminopropyl)carbamate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] N-(4-aminobutyl)-N-(3-aminopropyl)carbamate
• 化学式: C₃₅H₆₃N₃O₂
• 分子量: 557.9
• InChiKey: GPNOCMVRYHXLHP-SJTWHRLHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  40
• 可旋转键数：
  14
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  81.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS<br/>[FR] POLYNUCLÉOTIDES CODANT POUR UN RÉGULATEUR DE CONDUCTANCE TRANSMEMBRANAIRE DE LA MUCOVISCIDOSE POUR LE TRAITEMENT DE LA MUCOVISCIDOSE
  申请人：[en]MODERNATX, INC.

  公开号：WO2022104131A1

  公开（公告）日：2022-05-19

  This disclosure relates to delivery vehicles comprising payload molecules, e.g., mRNA or gene editing therapeutics for the treatment of cystic fibrosis (CF). Nucleic acid therapeutics (e.g., mRNAs) for use in the invention, when administered in vivo, encode cystic fibrosis transmembrane conductance regulator (CFTR). Nucleic acid therapeutics (e.g., mRNAs) of the disclosure increase and/or restore deficient levels of CFTR expression and/or activity in subjects. Nucleic acid therapeutics (e.g., mRNAs) of the disclosure further decrease abnormal accumulation of ammonia associated with deficient CFTR activity in subjects.